Market price and future trend forecast of filgotinib in 2025

Filgotinib (Filgotinib), as a selective JAK1 inhibitor, is mainly used to treat rheumatoid arthritis and other inflammatory diseases. In recent years, it has attracted increasing attention in the international market. As of2025, filgotinib has not been officially approved for marketing in mainland China, and domestic patients can only purchase the drug through overseas channels. Due to the lack of formal domestic sales channels, patients face higher purchasing difficulties and additional cost burdens.

In the international market, the original research version of filgotinib is more expensive. Taking the European version as an example, a box of 200mg×30 tablets costs about more than 10,000 yuan. This price reflects the comprehensive impact of drug research and development costs, production costs, as well as national medical insurance policies and market pricing. High prices limit drug accessibility for some patients, especially in areas with more limited economic conditions.

In order to reduce the cost of medication, some generic versions have also appeared on the market, mainly produced by manufacturers such as Laos Lucius. The specifications of these generic drugs are generally 100mg×30 tablets. The price is about 900 yuan, which is significantly lower than the original drug. The emergence of generic drugs provides patients with an affordable choice, but it also faces certain uncertainties in drug quality supervision and clinical efficacy. Patients need to be cautious when choosing.

Looking to the future, as the clinical application of filgotinib continues to expand globally, the possibility of domestic approval for marketing is gradually increasing. Once it is approved for domestic marketing and included in medical insurance, its price is expected to drop further and the burden on patients will be significantly reduced. At the same time, the generic drug market will continue to develop, making the overall price level more reasonable and helping to improve the accessibility and treatment coverage of filgotinib.

Reference materials:https://www.drugs.com/